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Introduction
The human malaria parasite, Plasmodium falciparum , is responsible for around one million deaths every year, mainly in sub-Saharan Africa, and the spread of resistance to affordable drugs has resulted in an increase in malaria-specific mortality over the past 10 years (Snow et al ., 2001) . P. falciparum is unique among the human malarias in undergoing a process of sequestration, whereby infected erythrocytes are withdrawn from the peripheral circulation through adhesion to post-capillary venular endothelium. This process of adhesion has been associated with severe disease, for example parasite accumulation in the brain and cerebral malaria (CM) (Turner, 1997) . The molecular mechanisms underlying disease are not understood, but parasite ligands and host receptors for the primary adhesive event have been characterized. A variant protein on the infected erythrocyte (IE) surface known as P. falciparum erythrocyte membrane protein 1 (PfEMP1) contains the binding sites for a range of endothelial receptors . This protein is encoded by a family of genes known as var (Baruch et al ., 1995; Smith et al ., 1995) , and switching between members of this gene family has been associated with changes in antigenicity and adherence phenotype (Biggs et al ., 1992; Roberts et al ., 1992; Smith et al ., 1995) . On the host side, there are a large number of receptors (for a review, see Craig and Scherf, 2001) , and a recent study has suggested that the ability of parasites to bind to multiple receptors is correlated with disease severity (Heddini et al ., 2001) . Intercellular adhesion molecule-1 (ICAM-1) has been shown to mediate IE adhesion (Berendt et al ., 1989 ) and, with CD36 (Barnwell et al ., 1989; Ockenhouse et al ., 1989; Oquendo et al ., 1989) , appears to be responsible for the majority of adhesion seen in isolates from children . Several lines of evidence have implicated ICAM-1 as having a role in severe disease: (i) adhesion to ICAM-1 was higher in isolates from patients with clinical malaria disease and tended to be higher in those with CM ; (ii) ICAM-1 in brain vessels co-localizes with sequestered parasites in autopsy samples from people dying from CM (Turner et al ., 1994) ; (iii) ICAM-1 expression on endothelium is upregulated during malaria infection (Turner et al ., 1998) ; and (iv) a genetic polymorphism in the N-terminal immunoglobulin (Ig)-like domain of ICAM-1 is associated with severe disease (Fernandez-Reyes et al ., 1997) . We have also shown recently that ICAM-1 can play a critical role in recruiting IE from flow (Gray et al ., 2003) and, along with others (McCormick et al ., 1997; Yipp et al ., 2000) , have shown that ICAM-1 and CD36 work synergistically in mediating adhesion to endothelium.
ICAM-1 is an 80-114 kDa variably glycosylated membrane glycoprotein consisting of five Ig-like domains that is expressed on the surface of a wide range of cell types (for a review, see van de Stolpe and van der Saag, 1996) . The binding site for IE has been characterized previously in two separate studies Ockenhouse et al ., 1992a) and appears to involve the BED 'side' of the N-terminal Ig-like domain (Fig. 1 ). This site is distinct, but shows some overlap with the binding sites for LFA-1 and human rhinovirus, and has a high level of overlap with the binding site for fibrinogen. The two studies used different ICAM-1-binding parasite lines ITO4 and ItG-ICAM, which have different avidities for ICAM-1 (Duperray et al ., 1997) , and different panels of ICAM-1 mutants, but both implicated regions close to each other on the crystal structure at positions G15, L18, T20 and L43 Ockenhouse et al ., 1992a) . Later work showed that a nat-ural polymorphism at position 29 in the BC loop, replacing a lysine residue with methionine, could also affect IE binding (Adams et al ., 2000; Craig et al ., 2000) . Therefore, we targeted residues G14 to L30 and K39 to K50 for alanine replacement mutagenesis (Cunningham and Wells, 1993) , covering much of the BED 'side' of the ICAM-1 molecule, and tested the resulting mutant proteins for their ability to bind erythrocytes infected with three different ICAM-1-binding parasite lines under static and flow conditions. Our results show that the binding site for IE is located on the BED side of the ICAM-1 molecule for all three parasite lines tested. Importantly, however, the repertoire of ICAM-1 mutants bound by the three parasite lines differed, indicating subtle differences in the contact residues used by different parasite lines.
Results

Characterization of mutant proteins
An important aspect of functional studies using mutagenesis is a screen for major disruption of conformation of the mutated protein. We used a panel of seven, conformationally sensitive, monoclonal antibodies (mAbs) to the Nterminal domain of human ICAM-1, which had been mapped to different regions of this domain, as probes for correct folding (Table 1) . Of the 25 mutant proteins used in this study, only two (C25/A and P28/A) had lost more than two mAb epitopes. For the C25/A mutant, this resulted in a complete abrogation of binding of all parasite lines under all conditions but, unusually, the P28/A mutant was still able to bind IE, indicating conservation of at least part of the structure. It is interesting to note that, although mutation of the cysteine at position 25 resulted in a loss of all mAb epitopes, changing the cysteine at position 21 had no effect on conformation. Mutant proteins not listed had no significant epitope loss.
Static adhesion assays
Binding of the three parasites lines to different ICAM-1 mutant proteins under static conditions is shown as a percentage of binding to ICAM-1 ref (Fig. 2) . The ItG line appears to be more sensitive to disruption of binding under static conditions, with six mutations ( 
Flow adhesion assays
The three parasite lines A4, ItG and JDP8 were tested for binding to the ICAM-1 mutants under flow conditions. Stationary binding of the three parasite lines to the different ICAM-1 mutants under flow is shown as a percentage of binding to ICAM-1 ref (Fig. 3) . In contrast to the results in static adhesion assays, a larger number of mutant ICAM-1 proteins affected stationary binding in flow assays. Seven ICAM-1 mutations caused a reduction of > 50% in A4 (V17/A, T20/A, C21/A, K29/M, K40/A, L42/A and L44/ A) and ItG adhesion (G15/A, V17/A, L18/A, S22/A, K40/ A, L42/A and L44/A), whereas eight mutants reduced JDP8 adhesion by > 50% (G15/A, V17/A, V19/A, S22/A, K39/A, K40/A, L42/A and L44/A). This higher number of mutants affecting binding under flow conditions reflects the higher sensitivity of the flow-based assay and may be more relevant in physiological terms, as there is some evidence to suggest that one of the major roles of ICAM-1 in IE adhesion is the initiation of tethers to host endothelium under flow (Gray et al ., 2003) . The only ICAM-1 mutant to increase binding was R49/A, particularly with A4 and, to a lesser extent, with ItG. Increases in mAb binding as a result of mutations in ICAM-1 have been reported previously and, although rarer than reductions in biological interactions, it is not inconceivable that a mutation near the binding site might act to increase access of the IE to its receptor. The distribution of velocities for IE rolling on mutant ICAM-1 proteins is shown in Fig. 4 . Although many of these show similar trends to the results seen in stationary cells (Fig. 3 ), a number of them indicate more subtle effects of the mutation. For example, the ItG/L44 result shows decreased stationary adhesion and a matching increase in the rolling velocities, indicating a general reduction in binding in both populations of IE, whereas JDP8/L18 has no effect on the stationary binding but has Fig. 4 . Velocity distributions of infected erythrocytes rolling on mutant ICAM-1 proteins. Cells with rolling velocities of at least 15 m ms -1 are plotted for the mutant proteins. Each dot represents a single parasitized red blood cell for which the rolling velocity was calculated from the videotape of the flow assay. The points for each protein represent the velocities measured over 1 min in six different areas of the microslide. The mean velocity is shown as a horizontal line. clearly shifted the distribution of rolling velocities upwards, suggesting a decrease in binding that is only seen in this population of cells. Other situations are harder to interpret, such as ItG/S22, where there is a complete loss of stationary adhesion but rolling adhesion is hardly affected. Uncoupling of the effects on stationary and rolling adhesion in malaria have been reported previously in a study examining the effect of src family kinase inhibitors on adhesion under flow (Yipp et al ., 2003) , although not via ICAM-1.
Variant parasite lines show differences in their adhesion to ICAM-1
In order to simplify the binding data for analysis, we have coded them into 'no difference', 'minor decrease', 'moderate decrease' and 'major decrease' (Table 2) . A comparison of the effects of different mutations on the adhesion of the three variant parasite lines shows that, although they share common binding regions (e.g. K40/A, L42/A and L44/A), they also have differences in their contact residues. The pattern produced for strain ItG agrees with the results of Ockenhouse et al . (1992a) , which showed that the region G14 to L18 was important for adhesion, but the use of more sensitive flow-based assays also shows that the DE loop is implicated in binding of this parasite line to ICAM-1. The similar pattern of mutations affecting the binding of ItG and the Indian isolate JDP8 (Okoyeh et al ., 1999) may be linked to their shared highavidity type binding to ICAM-1 (Gray et al ., 2003; Chattopadhyay et al ., 2004) . Although A4 had some residues in common with ItG and JDP8, several differences were seen (T20/A and K29/M), and A4 also differs from ItG and JDP8 in having a low-avidity ICAM-1-binding phenotype. Although there are differences between the ways in which the parasite lines interact with the mutant proteins, only two ICAM-1 mutants showed a major effect in one parasite line and not in at least one of the other lines, namely A4/ K29 and A4/R49. This suggests that the ability of IE to bind to ICAM-1 has a common origin, with subsequent changes in PfEMP1 altering the quantitative nature of the interaction. This is highlighted by the fact that all three parasite strains bound residues on b sheets B and D as well as DE loop of ICAM-1 (Fig. 5 ). However, A4 alone bound residues on the BC loop of ICAM-1 (Fig. 5 ).
Discussion
Mutagenesis using alanine replacements for residues in the binding region on ICAM-1 for P. falciparum -infected erythrocytes has allowed a detailed analysis of adhesion to this host receptor with three antigenically distinct, Results for flow assays are for stationary adhesion.
ICAM-1-binding parasite lines. Using a panel of mutant ICAM-1 proteins, we have been able to segregate these three isolates on the basis of disruption of adhesion by different alanine replacements. These results show that variant parasite lines have differences in their contact residues on the BED side of the molecule, as defined by the effect of mutations on their adhesive phenotype.
The association between antigenic type and cytoadherence has been known for some time (Biggs et al ., 1992; Roberts et al ., 1992) and is thought to be largely mediated by the parasite-derived protein PfEMP1 (Smith et al ., 1995) . This protein contains a number of domains that have been shown to mediate interactions with specific host receptors, including CD36 (Baruch et al ., 1997) , ICAM-1 (Smith et al ., 2000) and CR1 (Rowe et al ., 2000) among several others (for a review, see Craig and Scherf, 2001) . The exact nature of the parasite binding sites for these host receptors is not known, as attempts to define a consensus have been impeded by the high degree of sequence variation seen in these motifs (Smith et al ., 2001) . The N-terminal domain of ICAM-1 on the other hand is highly conserved, with only one major mutation (ICAM-1 Kilifi ) detected in African populations (Fernandez-Reyes et al ., 1997) . IE have been shown to interact with a region of this molecule that is distinct from, but overlaps, the binding sites for LFA-1, rhinovirus and fibrinogen Ockenhouse et al ., 1992a; Duperray et al ., 1997) . Indeed, the ICAM-1 Kilifi mutation (K29/M) has been shown to have effects on all these adhesive phenotypes A. Craig, unpublished observations) , placing it at an interesting cross-roads of functionality. The interaction between ICAM-1 and IE has been studied in some detail. As well as firm adhesion to ICAM-1-bearing substrates, IE from some parasite lines also demonstrate rolling behaviour (Cooke et al ., 1994) . This may be important in terms of capturing IE from the circulation, and it is assumed that this interaction results from high k on and k off rates between ICAM-1 and PfEMP1. However the basis of the partition between stationary and rolling adhesion on recombinant ICAM-1 protein is not known, nor is the lack of binding of so-called 'high-avidity' ICAM-1-binding lines to activated HUVEC (bearing high levels of ICAM-1 receptor) (Gray et al., 2003) . Previous data have segregated ICAM-1-binding IE into high-and low-avidity binders , represented in this work by parasite lines ItG and A4 respectively. JDP8 is a recently cultured patient isolate from Madhya Pradesh, India, that binds ICAM-1 with similar avidity to ItG but has relatively low binding to CD36 (Gray et al., 2003; Chattopadhyay et al., 2004) . Using a panel of mutant ICAM-1 Fig. 5 . Schematic representation of mutations having a major effect on IE binding to ICAM-1 mapped onto the three-dimensional structure of the N-terminal domain of ICAM-1. The positions of mutations having a major effect (<25% reference binding) on IE adhesion under static or flow assay conditions are marked with a circular dark blue zone. proteins, we have been able to segregate these three isolates on the basis of disruption of adhesion by different alanine replacements. As expected, flow-based adhesion assays are a more sensitive technique in defining responses to mutations, but even static assays are able to differentiate between parasite lines (see below).
The similar binding behaviour of ItG and JDP8 was reflected in the distribution of mutations affecting stationary binding under flow conditions for both parasite lines (Fig. 5 ). A4 shared a number of common mutations with ItG and JDP8 that reduce binding to ICAM-1, but also had some exclusive mutations that only affected its binding. Given the gross differences in binding of A4 and ItG/JDP8 to ICAM-1, it is tempting to speculate that the molecular basis of this differential binding is due to variation in the contact residues between ICAM-1 and PfEMP1, the parasite ligand that mediates the interaction. This situation is similar to that seen in human rhinovirus (HRV), in which cryoelectron microscopic reconstructions and comparison with X-ray crystal structure have shown subtle differences in the molecular interactions between ICAM-1 and the viral 'canyon', defined by proteins VP1, VP2 and VP3 in two major serotypes, HRV14 and HRV16 (Kolatkar et al., 1999) . As in malaria, the pathogenic consequences of these differences is not understood, but clear phenotypic differences exist in terms of ICAM-1 binding between HRV14 and HRV16.
In addition to the major differences between A4 and ItG/ JDP8 (Fig. 5) , there are a number of mutations that showed a differential effect on binding between ItG and JDP8. The clearest demonstration of this comes from static assays (Fig. 5) , with ItG showing much greater sensitivity to mutations than JDP8. Closer inspection of the data reveals that these differences are quantitative rather than simply 'binds' or 'does not bind'. It is rare for a major effect to be observed without some measurable effect being detected in another parasite line, the only case here being A4/K29. This suggests that the overall interaction between ICAM-1 and PfEMP1 is similar between variants and is indicative of a common origin of ICAM-1 binding for P. falciparum, at least within the isolates examined in this study. Despite this, it is relatively easy to design a panel of mutant proteins that would discriminate between A4, ItG and JDP8; for example, a set of assays under static and flow conditions using only two mutant proteins, S22/A and K29/M, would give definitive results. The use of this type of analysis on a larger scale for typing patient isolates in a field study would allow the definition of different ICAM-1-binding types and could be important, as a previous study has identified the ability of patient isolates to bind to ICAM-1 as being associated with clinical disease . Other results (C. Newbold, personal communication) indicate that isolates from CM patients tended to have higher ICAM-1 binding ('high avid-ity'), so it is possible that stratification of the ICAM-1binding isolates into subtypes might have produced a significant correlation between adhesive phenotype and CM. This information could also facilitate the elucidation of the mechanisms underlying severe disease, by providing the molecular basis of interactions associated with either mild disease or CM. The association between ICAM-1 adhesion and severe disease needs to be treated with some caution as, although there is some evidence supporting this, other data are contradictory. In one project looking at patient isolate adhesion profiles and disease, ICAM-1 binding was lower in isolates from children with cerebral malaria (Rogerson et al., 1999) , and genetic studies have shown both neutral (Bellamy et al., 1998) and protective (Kun et al., 1999) associations with the ICAM-1 Kilifi polymorphism. Resolution of these issues will require further examination of the adhesive behaviour of patient isolates from different disease categories.
Part of the rationale for mapping the sites of interaction between parasite ligands and host receptors is for the development of inhibitors of adhesion that may have therapeutic value as the ability to reverse adhesion could play a significant role in reducing severe malaria. The most highly developed work in antiadhesive therapies is in placental malaria (Gysin et al., 1999) and cytoadherence via CD36 (Yipp et al., 2002) , in which the binding sites have been mapped, and soluble proteins based on these structures have been shown to inhibit adhesion. For ICAM-1, it would clearly be desirable to have an inhibitor that would either be specific for highly pathogenic ICAM-1-binding lines or a pan-blocking molecule, able to interfere with all adhesion via ICAM-1. Our study has shown that the latter route might be possible using inhibitors based on the L42 loop (DE loop), as the L42/A mutation has a major effect under flow conditions on all three parasite lines. Indeed, this information has been used to screen a library of compounds as mimeotopes for the L42 loop structure in silico, producing a lead compound able to block adhesion of A4 and ItG to ICAM-1 protein (A. Craig, manuscript in preparation) . In addition to small-molecule inhibitors, the definition of the molecular interaction between ICAM-1 and PfEMP1 and the possible subcategorization of binding and progression to severe disease should also allow the development of a vaccine able to reduce disease (by blocking cytoadherence) while still permitting parasite carriage and the development of naturally acquired immunity.
ICAM-1 is thought to exist as a dimer on the cell surface (Reilly et al., 1995) with the interface formed by major contacts in domain 2, plus the BED face of the N-terminal domain (domain 1). Our previous work has also shown that the ICAM-1-Fc protein also exists as a dimer . Thus, the binding surface for LFA-1 is completely accessible on the outside of the dimer, whereas the P. falciparum binding site is located in the centre. It is possible that the parasite uses the physical proximity of the two binding faces at the core of the dimer to strengthen the interaction with PfEMP1, such that the parasite ligand sits within the 'groove' formed by the two ICAM-1 molecules. The broad nature of the P. falciparum binding footprint would also facilitate a multistep binding process, also seen in HRV (Kolatkar et al., 1999) , which could potentially separate the processes involved in adhesion or even those of adhesion and signalling.
One of the characteristics of immunoglobulin superfamily members that bind integrins (such as ICAM-1/LFA-1) is the presence of two disulphide bonds in the Nterminal domain (Wang and Springer, 1998) , in contrast to the 'normal' arrangement of only one. The 'extra' disulphide bond in ICAM-1 is located at the top of the domain, joining the BC loop to the F strand and includes the cysteine residue at position 25 (Fig. 1) . The other disulphide bond is located within the b-barrel and joins strands B and F, including the cysteine at position 21. Both these cysteines (C21 and C25) were replaced individually with alanine during this study, but only one of them, C25/A, resulted in a complete loss of conformation in the N-terminal domain, as shown by the loss of conformationally sensitive epitopes for a range of monoclonal antibodies (Table 1) , with no mAb deficit recorded for C21/A. This result indicates that, although other interactions within the b-barrel are able to compensate for the loss of the C21 disulphide bridge, removal of the C25 disulphide bond causes a major perturbation of the domain structure. This is rather counterintuitive as it might be expected that removal of this bond from a loop structure (loop BC) would have little effect, but it is possible that the correct orientation of this loop with respect to the rest of the domain is important or that removal of C25 may cause an incorrect pairing of the cysteine at the top of the F strand with C21. The involvement of the BC loop in the conformation of the N-terminal domain is strengthened by the observation that the P28/A mutant also shows the loss of multiple mAb epitopes.
Using a panel of ICAM-1 mutant proteins, we have shown that three different ICAM-1-binding parasite lines bind to a similar region of the ICAM-1 molecule, but that differences exist in the contact residues used. These differences appear to correlate with the type of binding to ICAM-1, with the low-avidity A4 having a markedly different 'footprint' compared with ItG and JDP8. Even the two high-avidity binders show subtle differences, with ItG being much more sensitive to the effect of mutations under static assay conditions. The ability to subdivide ICAM-1 adhesion of IE into different categories may contribute to the definition of the mechanisms underlying progression to severe disease, and thereby facilitate the design of therapeutic interventions, either through specific inhibitors designed to localized regions of the ICAM-1 molecule or the transfer of contiguous, non-linear epitopes to a smallmolecule framework (Gadek et al., 2002) .
Experimental procedures
Parasite culture
Plasmodium falciparum parasites were grown in group O + human erythrocytes using previously described conditions (Trager and Jensen, 1976) . To minimize the effect of antigenic switching in culture, a batch of stabilates was prepared from ICAM-1-selected cultures, which were serially thawed and maintained in culture for not more than 3 weeks. Lines A4 (Roberts et al., 1992) and ItG (Ockenhouse et al., 1992b) are both from the IT lineage and are of Brazilian origin. JDP8 (Okoyeh et al., 1999; Chattopadhyay et al., 2003) is a recently identified patient isolate from Jagdalpur, Madhya Pradesh, India.
ICAM-1 mutagenesis and protein expression
Single amino acid substitutions were introduced into the human ICAM-1 cDNA, cloned as an IgG1-Fc chimera , using the incorporation of mismatched mutagenic oligonucleotide primers (QuikChange, Stratagene). A list of the primers used in this study is shown in Table 3 .
Mutagenesis was attempted on all residues from G14 to L30 and K39 to K50 but, despite repeated attempts, it was not possible to produce some mutants. This included K29/A, and so the natural mutation K29/M, ICAM-1 Kilifi , was used for the study. DNA minipreps (Qiagen) were sequenced to screen for the correct mutations [and lack of other, polymerase chain reaction (PCR)-induced, non-specific mutations], and successful constructs were resequenced after maxipreps of plasmid DNA for transfection had been produced.
Expression of the ICAM-1-Fc constructs was carried out essentially as described previously by transfection of COS7 cells using Fugene-6 (Roche) according to the manufacturer's instructions. Each protein was tested for structural integrity by enzyme-linked immunosorbent assay (ELISA) using a panel of six mAbs that had previously been mapped to the N-terminal domain [RR1/1, My13, 15.2 (Serotec), 170/6 (G. Turner), BBA4 (R and D Systems) and 7.5C2 (D. Haskard)] and two mAbs from the C-terminal domain [GP89-14 and GP89-23 (J. Johnson)], used as reporters of protein concentration.
Parasite adhesion assays
Static protein-binding assays were performed as described previously using an ICAM-1-Fc spotting concentration of 25 mg ml -1 , which had previously been shown to be within the dynamic range for detecting differences in adhesion. All mutant proteins were screened twice, in duplicate dishes, with those showing an effect being included in two further rounds of experiments. Data shown are the mean of all experiments. Flow assays on protein-coated microslides were also performed using standard conditions (Cooke et al., 1994) , with a coating concentration of ICAM-1-Fc of 50 mg ml -1 . All proteins were tested in duplicate in three separate experiments. Small variations in the concentrations of mutant proteins were corrected for using the ELISA results for GP89-14 and GP89-23. All results are expressed as percentage binding of the relevant parasite isolate to that seen on an equivalent concentration of ICAM-1 ref . Statistical significance was determined using the Tamhane T-2 test, with differences regarded as significant if P < 0.05.
Results have been placed into three main groups (plus one example of an increase in binding) ( Table 2) to aid interpretation of the results. Owing to the inherent variability of binding assays, some results that would normally have been coded as a moderate decrease were not statistically significant and have been left as 'no difference'. All 'major decrease' results were highly significant.
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